News & Analysis as of

Food and Drug Administration (FDA) Nominations

Foley & Lardner LLP

What’s Next in Washington? - April 2022

Foley & Lardner LLP on

While Congress has a two-week recess in April, there are many priority items on the agenda this month. Less than two weeks after signing the Fiscal Year (FY) 2022 spending package, President Biden released his budget for FY...more

Clark Hill PLC

Window on Washington - This Week in the Nation's Capital - Vol. 1, Issue 13

Clark Hill PLC on

Internal House GOP Budget Feud Threatens Agenda: House GOP efforts to write a fiscal 2018 budget are deadlocked amid Republican infighting, a divide that threatens to undermine President Donald Trump’s agenda by stalling tax...more

Morrison & Foerster LLP - Class Dismissed

Trump’s Nominee for FDA Commissioner Likely Dooms Generic Drug Labeling Rule

President Trump recently announced his intent to nominate a new commissioner of the U.S. Food and Drug Administration (FDA), likely sealing the fate of FDA’s proposed generic drug labeling rule. The proposed rule would give...more

Mintz - ML Strategies

Health Care: What's on the Radar for This Congressional Work Period

Mintz - ML Strategies on

The next Hill work period basically runs from February 22 to March 18. As Congress returns, here’s a brief look at the pending health care issues on the radar for this work period....more

McGuireWoods LLP

FDA Commisioner Hamburg to Step Down: Ostroff Acting Until New Commissioner Named

McGuireWoods LLP on

On February 5, FDA announced that FDA Commissioner Margaret Hamburg, M.D. has reportedly informed agency colleagues via en e-mail that she will step down as Commissioner at the end of March 2015. ...more

5 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide